CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
Anamorelin Hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04021706
NCT04021706Phase 1Completed
CompareCT.gov

Effect of a Ghrelin Receptor Agonist on Muscle and Bone

Tufts University·interventional·Posted Jul 16, 2019·Updated Mar 27, 2024

In Brief

A Phase 1 clinical trial evaluating Anamorelin Hydrochloride and Placebo for Sarcopenia and Osteopenia. Completed, enrolled 32 participants across 1 site.

Detailed Summary

Adults with low muscle mass also usually have low bone mass, making them vulnerable to falls, fractures and other injuries. This project will determine the effectiveness of treatment with a ghrelin receptor agonist in improving short term indicators of muscle and bone health in adults with low bone and muscle mass. The results of this trial will inform the design of a larger, definitive randomized trial designed to establish efficacy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcopenia, Osteopenia
CountriesUnited States
CollaboratorsNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJul 16, 2019
Enrollment StartDec 5, 2019
Primary CompletionJan 26, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.0 years ago

Interventions

Anamorelin Hydrochloridedrug

Ghrelin receptor agonist

Placebodrug

placebo is a inert substance